( EuronextBrussels:THR )

News from thrombogenics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 08, 2016, 01:30 ET ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the...


Jun 08, 2016, 11:40 ET ThromboGenics Receives US FDA Approval for New 'Already-Diluted' Formulation of JETREA®

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today...


May 13, 2016, 01:30 ET ThromboGenics Business Update - Q1 2016

Developing Novel Medicines Targeting Diabetic Eye Disease    Highlights  - ThromboGenics is focused on developing novel...


Apr 27, 2016, 02:00 ET New Ocriplasmin Research Findings Presented

New Data Confirm Appropriate Patient Selection Leads to Improved Treatment Outcomes, With no new Safety Signals Observed  ThromboGenics NV...


Mar 01, 2016, 02:00 ET ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments...


Jan 13, 2016, 01:30 ET ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy...


Mar 04, 2014, 01:30 ET ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US

Ocriplasmin Research to Better Inform Treatment (ORBIT) study designed to generate further data on the "real world" use of...


Dec 06, 2013, 18:03 ET ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

Dr Staf Van Reet appointed as new Chairman of the Board ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company...


Dec 03, 2013, 01:30 ET J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014

Permanent J-Code J7316 will lead to streamlined reimbursement of JETREA® in the US ThromboGenics NV (Euronext Brussels: THR), an integrated...